Voyager Therapeutics Inc. (VYGR) Trading 1.4% Higher
Voyager Therapeutics Inc. (NASDAQ:VYGR)’s share price traded up 1.4% during trading on Wednesday . The stock traded as high as $16.48 and last traded at $16.18, with a volume of 56,505 shares traded. The stock had previously closed at $15.96.
Several equities analysts have recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Voyager Therapeutics in a research report on Thursday, August 11th. Piper Jaffray Cos. set a $37.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 26th. Finally, Stifel Nicolaus assumed coverage on shares of Voyager Therapeutics in a research report on Thursday, July 14th. They set a “buy” rating and a $33.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.25.
The firm’s market cap is $434.60 million. The stock has a 50-day moving average price of $13.61 and a 200 day moving average price of $11.86.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. Equities analysts expect that Voyager Therapeutics Inc. will post ($1.49) EPS for the current fiscal year.
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.